BioDelivery Sciences International is a specialty pharmaceutical company leveraging its novel and proprietary patented drug delivery technologies to develop and commercialize new applications of proven therapeutics – either independently or in partnerships with third parties. The company is currently focused on developing products to meet unmet patient needs in pain management and addiction, and its pain franchise presently consists of two products utilizing the patented BEMA technology – ONSOLIS and BEMA Buprenorphine, both in Phase 3 clinical development. For more information, visit the company’s Web site at www.bdsi.com.

The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. Each year the annual event provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. For more information on Biotechnology Industry Organization (BIO), visit www.bio.org.

Let us hear your thoughts below: